603 filings
Page 5 of 31
8-K
d95caw
2 Jun 21
Protalix Biotherapeutics and Chiesi Global Rare Diseases Provide Update Regarding Clinical Development of PRX-102 for Treatment of Fabry Disease
7:02am
8-K
x1l lehjtgbp83kfuoc
14 May 21
Protalix BioTherapeutics Reports First Quarter 2021 Financial Results and Business Update
6:56am
8-K
onxw95gytnu8 s0qxr5f
28 Apr 21
Protalix BioTherapeutics and Chiesi Global Rare Diseases Receive Complete Response Letter for Pegunigalsidase Alfa from FDA
6:04am
8-K
3jezic1i
30 Mar 21
Protalix BioTherapeutics Reports Fiscal Year 2020 Financial and Business Results
7:02am
8-K
h4ab8g
23 Feb 21
Study achieved key objectives for safety, efficacy and pharmacokinetics
7:01am
424B5
pm42289 n0
16 Feb 21
Prospectus supplement for primary offering
6:22am
8-K
0c1q24ga
16 Feb 21
Protalix BioTherapeutics Announces Proposed Public Offering of Common Stock
12:00am
424B5
cur1 o6z26ad
11 Feb 21
Prospectus supplement for primary offering
5:03pm
8-K
q54g8edjy3lu3
30 Dec 20
Regulation FD Disclosure
7:10am
8-K
r0ljsq2g5ctr4v
29 Oct 20
Protalix BioTherapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
7:12am
8-K/A
5tsudy6h
23 Oct 20
Submission of Matters to a Vote of Security Holders
5:01pm
8-K
exeybch rmu
1 Oct 20
Entry into a Material Definitive Agreement
5:21pm
424B5
8myazo
1 Oct 20
Prospectus supplement for primary offering
5:15pm
8-K
r8plft oemu3
8 Sep 20
Other Events
7:53am
8-K
vfbflsemwri8
11 Aug 20
Other Events
6:54am